Skip to content

NYSE · large · thesis board

JNJ Johnson & Johnson

CD38 mAb / myeloma franchise (Darzalex)

View race

Thesis

Editorial summary — not a primary filing

Darzalex CD38 franchise plus Carvykti partnership anchor hematology oncology.

Next gate

2026-09-12Company-guidedlabel expand

Myeloma franchise update

30 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~30 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~950d)100%
Days to gate (30d)3%
Show math

$25.0B cash ÷ $800M/mo burn ≈ 950 days. Source: curated SEC quarter figures.

Cash $25.0B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
LEGNApprovedokBMYApprovedokREGNPh3ok

Risks

  • Biosimilar pressure over time
  • Pipeline prioritization
  • Litigation
  • Pricing

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT02076009as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01